Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates CBIO Bearish with a Setup Score of 35, net conviction 37, actionability 34. How the Setup Score works →
Total Setup Score
35
Directional Bias
Bearish
Net Conviction
37
Actionability
34 (in range)
Key signals behind this score
Fresh Breakdown — 10wk turn 1w
80wk Downtrend — falling+below (sma 17.59 vs px 17.09)
200wk Downtrend — falling+below (sma 93.43 vs px 17.09)
Short Attack — velZ +1.00 · age 13w×1.00 · 23.73%
Seasonal Headwind — july med -3.6% (mag 1/3) · posClose 33.33% (rel 2/3) · n12 ×1 = 8.8
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: January 10, 2014
Headquarters: 300 Fifth Avenue, Waltham, MA, United States, 02451
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$18.74
Near-term / short-term trend
Weekly
40-Week SMA
$14.68
Medium-term trend
Weekly
80-Week SMA
$17.59
Cyclical trend (business cycle)
Weekly
200-Week SMA
$93.43
Secular trend (multi-year)
Monthly
10-Month SMA
$15.78
Near-term monthly trend
Monthly
20-Month SMA
$17.93
Medium-term monthly trend
Monthly
40-Month SMA
$77.87
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$11.40
support
1.50x
3 months ago
$9.50
support
1.67x
4 months ago
$180.00
resistance
5.88x
25 months ago
Historical Earnings Reactions (49 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.08%
0.00%
44.90%
10.99%
-5.90%
1 Day
0.34%
-0.88%
46.94%
19.51%
-9.09%
1 Week
3.39%
0.00%
48.98%
153.66%
-65.73%
2 Weeks
7.00%
1.34%
55.10%
240.62%
-63.24%
1 Month
5.99%
-0.75%
50.00%
198.97%
-66.16%
Next earnings: July 30, 2026 (25 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
0.2%
41.7%
12
Feb
0.5%
53.8%
13
Mar
-0.9%
38.5%
13
Apr
-4.3%
46.2%
13
May
8.0%
46.2%
13
Jun
-3.1%
30.8%
13
Jul
-5.8%
33.3%
12
Aug
-5.3%
41.7%
12
Sep
-6.0%
16.7%
12
Oct
10.9%
50.0%
12
Nov
29.0%
75.0%
12
Dec
-3.1%
25.0%
12
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.47%
44.3%
587
Tuesday
0.50%
43.7%
646
Wednesday
-0.23%
43.7%
643
Thursday
0.27%
45.4%
630
Friday
0.24%
46.6%
627
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 96.4%
Insider Transactions — Smart Summary
Total insider ownership: 5.7%
12-Month Insider Activity Summary
Total Filings
8
Net Value
-$1.2M
Net Shares Change
1,291,844
% of Float
9.2%
C-Suite Filings
7
Clusters Detected
1
Key Insiders
Name
Title
Net Value
Filings
Activity
Fairmount Funds Management LLC
+$18.2M
1
1 buy
Brumm Joshua T
Chief Executive Officer
-$761,066.95
1
N/A
McNeill Jonathan
President and COO
-$369,676.51
1
N/A
Pinkas Jan
Chief Scientific Officer
-$23,171.12
1
N/A
Im Ellie Eunkyung
Chief Medical Officer
-$21,929.81
1
N/A
Bispham Barbara Harlin
General Counsel and Corporate Secretary.
-$21,911.82
1
N/A
Scalzo Richard William
Chief Financial Officer
-$20,004.88
1
N/A
Lynch Ryan
Treasurer, Senior Vice President of Finance and Chief Accounting Officer.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Crescent Biopharma, Inc.
(CBIO) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.